CA2108282A1 - Quantitative clotting assay for activated factor vii - Google Patents

Quantitative clotting assay for activated factor vii

Info

Publication number
CA2108282A1
CA2108282A1 CA002108282A CA2108282A CA2108282A1 CA 2108282 A1 CA2108282 A1 CA 2108282A1 CA 002108282 A CA002108282 A CA 002108282A CA 2108282 A CA2108282 A CA 2108282A CA 2108282 A1 CA2108282 A1 CA 2108282A1
Authority
CA
Canada
Prior art keywords
assay
factor
factor viia
viia
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002108282A
Other languages
French (fr)
Other versions
CA2108282C (en
Inventor
James H. Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
James H. Morrissey
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James H. Morrissey, Oklahoma Medical Research Foundation filed Critical James H. Morrissey
Publication of CA2108282A1 publication Critical patent/CA2108282A1/en
Application granted granted Critical
Publication of CA2108282C publication Critical patent/CA2108282C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Abstract

An assay for activated factor VII (factor VIIa) has been developed using truncated tissue factor (TF), a soluble mutant form of TF that retains the cofactor function of TF toward factor VIIa Unlike full-length TF, however, tTF appears not to sup-port the conversion of factor VII to VIIa. As a result, the tTF assay for factor VIIa is free from interference from factor VII in the plasma and is therefore specific for factor VIIa. The assay is much simpler than existing assays, because it is a single-stage clot.
ting assay performed almost identically to a PT assay. It is also considerably more sensitive than current assays for factor VIIa in plasma. Since he tTF assay is calibrated against a factor VIIa standard, it yields an absolute concentration of factor VIIa in ng/
ml.
CA002108282A 1991-04-10 1992-04-09 Quantitative clotting assay for activated factor vii Expired - Lifetime CA2108282C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/683,682 US5472850A (en) 1991-04-10 1991-04-10 Quantitative clotting assay for activated factor VII
US683,682 1991-04-10
PCT/US1992/002898 WO1992018870A1 (en) 1991-04-10 1992-04-09 Quantitative clotting assay for activated factor vii

Publications (2)

Publication Number Publication Date
CA2108282A1 true CA2108282A1 (en) 1992-10-11
CA2108282C CA2108282C (en) 2003-09-09

Family

ID=24745031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002108282A Expired - Lifetime CA2108282C (en) 1991-04-10 1992-04-09 Quantitative clotting assay for activated factor vii

Country Status (10)

Country Link
US (3) US5472850A (en)
EP (1) EP0641443B1 (en)
JP (1) JP3047120B2 (en)
KR (1) KR940700679A (en)
AT (1) ATE185901T1 (en)
AU (1) AU663713B2 (en)
CA (1) CA2108282C (en)
DE (2) DE641443T1 (en)
ES (1) ES2072243T3 (en)
WO (1) WO1992018870A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
ES2115679T3 (en) * 1991-10-04 1998-07-01 Dade Behring Inc PREPARATION OF PROTROMBINE TIME REAGENTS FROM RECOMBINANT HUMAN TISSUE FACTOR AND PURIFIED NATURAL AND SYNTHETIC PHOSPHOLIPIDS.
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
US7169572B1 (en) 1993-01-29 2007-01-30 T.A.C. Thrombosis And Coagulation Ab Assays for determining anticoagulant cofactor activity
DE19538716A1 (en) * 1995-10-18 1997-04-24 Behringwerke Ag Method for quantification of activated coagulation factor VII (FVIIa)
DE19531637A1 (en) * 1995-08-28 1997-03-06 Immuno Ag Pharmaceutical composition for the treatment of blood coagulation disorders, method for the production thereof and their use
DE19538715A1 (en) 1995-10-18 1997-04-30 Behringwerke Ag Process for cleaning factor VII and activated factor VII
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
EP0988056B1 (en) 1997-01-22 2003-07-09 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
WO1998045713A1 (en) * 1997-04-09 1998-10-15 Blutspendedienst Der Drk-Landesverbände Nordrhein- Und Westfalen-Lippe Gmbh Method for determining activated coagulation factors in plasma and plasma derivatives
DE19714559C1 (en) * 1997-04-09 1998-08-06 Blutspendedienst Der Drk Lande Determination of activated clotting factors in plasma
ATE311601T1 (en) * 1997-04-23 2005-12-15 Instrumentation Lab Spa RECOMBINANT RABBIT TISSUE FACTOR BASED PROTHROMBIN TIME REAGENT
DE19720853A1 (en) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Increasing the FVII sensitivity of a thromboplastin reagent
US6245573B1 (en) 1998-02-12 2001-06-12 University Of Medicine And Dentistry Of New Jersey Rapid assessment of the coagulant activity of blood
ID26107A (en) 1998-02-27 2000-11-23 Pamgene Bv METHODS FOR AMPLIFICATION NOT SPECIFIC OF NUCLEIC ACID
EP1067879B1 (en) * 1998-04-01 2007-02-28 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6403381B1 (en) 1998-06-08 2002-06-11 University Of Vermont And State Agriculture College Inhibition of coagulation in blood and blood products
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) * 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7110118B2 (en) * 2000-12-19 2006-09-19 Trustees Of Boston University Spectral imaging for vertical sectioning
DE10064689B4 (en) * 2000-12-22 2004-08-05 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Procedure for determining blood cell hemostasis
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
EP1260817A3 (en) * 2001-05-08 2002-12-18 Warner-Lambert Company Method for direct measurement of coagulation factor VIIa activity in plasma
ES2407355T3 (en) * 2001-07-03 2013-06-12 Oklahoma Medical Research Foundation Test to measure factor VIIa-antithrombin complexes
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
BR0215216A (en) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Liquid aqueous composition, method for preparing a liquid aqueous composition of a factor vii polypeptide, use of a liquid aqueous composition, and method for treating a factor vii response syndrome
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
HUE037603T2 (en) 2002-06-21 2018-09-28 Novo Nordisk Healthcare Ag Stabilised solid compositions of factor VIIa polypeptides
AU2003290663A1 (en) * 2002-11-13 2004-06-03 Haematologic Technologies, Inc. Assay for tissue factor and factor viia
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (en) 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Protein stabilization in solution.
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
KR20060109950A (en) * 2003-12-19 2006-10-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Stabilised compositions of factor vii polypeptides
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
WO2006088741A2 (en) * 2005-02-16 2006-08-24 The Board Of Trustees Of The University Of Illinois Procoagulants based on metal-chelating lipids
ATE505488T1 (en) * 2005-03-04 2011-04-15 Univ Illinois MODULATOR OF COAGULATION CASCADES AND FIBRINOLYTIC CAScades
FR2910969B1 (en) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement METHOD FOR MEASURING VIIA FACTOR CONCENTRATION (FVIIA) IN A SAMPLE
WO2009046274A1 (en) * 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
WO2009046194A2 (en) * 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
FR2933496B1 (en) * 2008-07-02 2012-10-05 Lfb Biotechnologies METHOD OF MEASURING ACTIVE FACTOR VII RATE IN A SAMPLE
DE102009048199A1 (en) * 2009-10-05 2011-04-21 Siemens Healthcare Diagnostics Products Gmbh Method for the determination of factor XIII using reference material based on plasma
EP2494040B1 (en) 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Method of producing recombinant vitamin k dependent proteins
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
JP6844890B2 (en) * 2016-01-07 2021-03-17 藤森工業株式会社 Blood collection tubes, reagents, and blood property analysis methods using them
JP6626761B2 (en) * 2016-03-30 2019-12-25 シスメックス株式会社 Prothrombin time measuring reagent and method for producing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479938A (en) * 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
ES2037664T3 (en) * 1985-11-26 1993-07-01 Novo Nordisk A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGIC DISORDERS.
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
AU1872992A (en) 1992-11-17
US5472850A (en) 1995-12-05
US5750358A (en) 1998-05-12
WO1992018870A1 (en) 1992-10-29
DE69230183T2 (en) 2000-08-31
US5741658A (en) 1998-04-21
DE69230183D1 (en) 1999-11-25
ES2072243T3 (en) 2000-03-16
AU663713B2 (en) 1995-10-19
ES2072243T1 (en) 1995-07-16
DE641443T1 (en) 1995-10-12
KR940700679A (en) 1994-02-23
JP3047120B2 (en) 2000-05-29
JPH06506601A (en) 1994-07-28
EP0641443B1 (en) 1999-10-20
EP0641443A1 (en) 1995-03-08
CA2108282C (en) 2003-09-09
ATE185901T1 (en) 1999-11-15

Similar Documents

Publication Publication Date Title
CA2108282A1 (en) Quantitative clotting assay for activated factor vii
CA2161881A1 (en) High lysine derivatives of alpha-hordothionin
CA2186618A1 (en) Novel aryl-n-alkylacridanthiocarboxylate derivatives useful for chemiluminescent detection
USD304659S (en) Combined chip and salsa server
EP1048659A4 (en) Retinoid receptor agonists
ES2044718T3 (en) PREPARATION CONTAINING ENZYMES AND DETERGENT CONTAINING SUCH PREPARATION.
SG90003A1 (en) Use of 4' of 5'-hydroxy and 4'- or 5'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods
AU2885589A (en) Composition of anticoagulants
AU588626B2 (en) Compound 1,4-diisopropyl-2,5-diketopiperazine
AU4072485A (en) Novel compounds
ES2164331T3 (en) PROLONGED RELEASE TABLETS BASED ON METAL VALPROATO.
HU9502190D0 (en) Novel anticoagulant cofactor activity
USD301017S (en) Orienteering compass
AU4149189A (en) Self fixturing structural adhesives
EP0878551A3 (en) Enhancement of the factor-VII sensitivity of a thromboplastin reagent
USD282203S (en) Chemical analyzer
AU2300292A (en) Chromogenic substrates for improving detection in a peroxidase-based assay
USD275851S (en) Control panel for a flue gas analyzer system
EP0352547A3 (en) Ldh1 assay
AU2804989A (en) Novel human tissue-type plasminogen activator variant
AU7100687A (en) Extinction type detector
AU625540B2 (en) High sensitivity detection of peroxidase activity
USD295746S (en) Front panel for an amplifier or the like
USD412991S (en) Enclosure for analytical instrumentation
USD282837S (en) Ion source control panel

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry